Jennifer Barton, MD MCR

Dr. Barton is an academic rheumatologist. She is a federally funded health services researcher with a focus is on patient-clinician communication and the rheumatic diseases. Dr. Barton is a prior recipient of a K23 award from NIAMS to examine goal concordance between diverse populations with rheumatoid arthritis (RA) and their rheumatologists. She is currently the PI of a VA HSR funded Merit Review entitled “Implementation of Shared Decision Making in Rheumatoid Arthritis: A stepped wedge, cluster-randomized trial” (NCT 05530694) to examine the impact of a multicomponent shared decision-making intervention on RA disease activity and measures of shared decision-making. Dr. Barton is a co-investigator of the Veterans Affairs Rheumatoid Arthritis (VARA) Registry and a local site investigator on a multi-site VA RRD Study, “A remotely applied behaviorally designed intervention incorporating gamification, social incentives, and health coaching to improve durability of physical therapy for knee osteoarthritis (ReAKTIV).” A fellow may contribute to any of the following projects: (1) Secondary data analysis from the VARA registry or national VA data; (2) Secondary data analysis of survey data from the K23 study on goal concordance in RA; (3) Quality improvement projects utilizing national rheumatology dashboards (e.g., hydroxychloroquine dosing, gout, DMARD latent infections, vaccinations).

Selected Publications:

1. Schmajuk G, Ware A, Li J, Tarasovsky G, Shiboski S, Barton JL, Miller KL, Mitchell HA, Dana J, Reiter K, Wahl E, Rozenberg-Ben-Dror K, Hauser RG, Whooley MA. National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease-modifying agent users within the Veterans Health Administration. Health Serv Res. 2025 Feb;60(1).
2. McGoldrick J, Molina-Ochoa D, Schwab P, Edwards ST, Barton JL. An Evaluation of Burnout Among US Rheumatology Fellows: A National Survey. J Rheumatol. 2023 Sep;50(9):1185-1190.
3. Singh N, Grivas P, Makris UE, Suarez-Almazor ME, O'Hare AM, Barton JL. Use of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision-Making Between Patients With Cancer and Clinicians. ACR Open Rheumatol. 2023 Jun;5(6):305-307
4. Barton JL, Markwardt S, Niederhausen M, Schue A, Dougherty J, Katz P, Saha S, Yelin EH. Are We on the Same Page? A Cross-Sectional Study of Patient-Clinician Goal Concordance in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023 Mar;75(3):625-633.
5. Hulen E, Larsen C, Matsumoto R, Katz P, Barton JL. "You can't touch, you can't bond": Exploring COVID-19 pandemic impacts on rheumatoid arthritis patient goals and communication with clinicians. Musculoskeletal Care. 2023 Mar;21(1):244-248.

Mohamad Bittar, MD MS

Dr. Bittar is an academic rheumatologist with a focus on clinical research. His research interest is studying pain mechanisms, especially nociplastic pain, in axial spondyloarthritis. He is supported by grants from the OHSU foundation and the spondyloarthritis research and treatment network (SPARTAN). Current ongoing and future projects include: 1- characterizing nociplastic pain in axial spondyloarthritis: a prospective study assessing the prevalence of nociplastic pain in axSpA at OHSU. Patients undergo quantitative sensory testing and fill out nociplastic pain questionnaires. 2- Portland Registry of Spondyloarthritis (PROS): collect data and outcome measures systematically on spondyloarthritis patients. 3- a study that will start soon to evaluate CNS dysregulation in axSpA patients by utilizing functional brain imaging.  A trainee may contribute to any of the above projects by assisting with data collection and data analysis.

Selected Publications:

1. Bittar M, Deodhar A. Axial Spondyloarthritis: A Review. JAMA. 2025 Feb 4;333(5):408-420. doi: 10.1001/jama.2024.20917. PMID: 39630439. 

2. Kommineni K, Abutineh I, Chapman C, Pattanaik D, Bittar M. Axial Spondyloarthritis in Black Americans: An Observational Study From Five Centers in Shelby County, Tennessee. ACR Open Rheumatol. 2025 Jan;7(1):e11769. doi:10.1002/acr2.11769. Epub 2024 Nov 27. PMID: 39601201; PMCID: PMC11694252. 

3. Bittar M, Deodhar A. A critical view of WHO guidelines on management of low back pain. Nat Rev Rheumatol. 2024 Apr;20(4):201-202. doi:10.1038/s41584-024-01088-7. PMID: 38355843. 

4. Bittar M, Nouer SS, Tolley EA, Dubreuil M, Magrey M. Mortality and Ankylosing Spondylitis in the US population: leading causes and associated factors. Clin Rheumatol. 2024 Jan;43(1):227-232. doi: 10.1007/s10067-023-06776-5. Epub 2023 Sep 21. PMID: 37733078. 

5. Bittar M, Merjanah S, Alkilany R, Magrey M. Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database. BMC Rheumatol. 2022 Jun 30;6(1):44. doi: 10.1186/s41927-022-00275-x. PMID: 35768880; PMCID: PMC9245256.

Cong-Qiu Chu, MD, PhD

Dr. Chu is a physician-scientist at the VA Portland Health Care System whose career has focused on bench-based research in the pathogenesis of rheumatoid arthritis (RA) and cartilage regeneration for the treatment of osteoarthritis. His early work identified overexpression of tumor necrosis factor (TNF) and TNF receptors in the inflamed synovium and cartilage-pannus junction, key sites of joint damage in RA, laying the scientific groundwork for the development of TNF-blocking therapies. His previous research includes developing aptamer-mediated targeted delivery of RNA interference (RNAi) to Th17 cells for treating RA and other inflammatory diseases; identifying single-stranded DNA aptamers that specifically bind to human TNF as potential therapeutic agents; investigating novel therapeutics targeting fibroblasts in RA; and exploring strategies for regenerating articular cartilage in osteoarthritis models. Dr. Chu’s current work emphasizes translational and clinical research, and he serves as the site principal investigator for a clinical trial evaluating CAR-T cell therapy in refractory RA. In addition to his research, Dr. Chu leads efforts to expand the division’s research portfolio and actively mentors fellows in scholarly activities such as writing review articles and conducting retrospective studies.

Selected Publications:

1. Wu T, Li Y, Liu Y, Chu CQ. Preclinical RA: How to halt its progression. Best Pract Res Clin Rheumatol. 2025 Mar;39(1):102030. doi:10.1016/j.berh.2024.102030. Epub 2024 Dec 24. PMID: 39721896.
2. Scanzello CR, Hasty KA, Chung CB, Griffin TM, Willet NJ, Krug H, Chu CQ, Ewart D, Jerban S, Baker JF, Duvall CL, Brunger JM, Burdick JA, Spindler KP, Drissi H. Teaming up to overcome challenges toward translation of new therapeutics for osteoarthritis. J Orthop Res. 2024 Dec;42(12):2659-2672. doi: 10.1002/jor.25944. Epub 2024 Aug 5. PMID: 39103981.
3. Chu CQ, Quan T. Fibroblast Yap/Taz Signaling in Extracellular Matrix Homeostasis and Tissue Fibrosis. J Clin Med. 2024 Jun 7;13(12):3358. doi: 10.3390/jcm13123358. PMID: 38929890; PMCID: PMC11204269.
4. Zhang X, Jozic A, Song P, Xu Q, Shi X, Wang H, Bishop L, Struthers HM, Rutledge J, Chen S, Xu F, Hancock MH, Zhu D, Sahay G, Chu CQ. mRNA vaccine against fibroblast activation protein ameliorates murine models of inflammatory arthritis. Rheumatol Immunol Res. 2023 Jul 22;4(2):90-97. doi:10.2478/rir-2023-0013. PMID: 37818347; PMCID: PMC10561064.
5. Chu CQ. Fibroblasts in rheumatoid arthritis. New England Journal of Medicine, 2020, 383:1679-1681

Atul Deodhar, MD

Dr. Deodhar has been dedicated to spondyloarthritis research (axial spondyloarthritis and psoriatic arthritis), including epidemiology, diagnosis, treatment guideline development and clinical trials of novel agents. Together with the Department of Dermatology, he has created the Center for Psoriasis and Psoriatic Arthritis Excellence (CEPPA) at OHSU, a multidisciplinary clinic which has provided care for patients with psoriasis and psoriatic arthritis and allowed the collection and analysis of a CEPPA registry. He is the site investigators of multiple clinical trials ranging from evaluating the efficacy of rapcabtagene (CD19 CAR-T-Cell therapy) in lupus nephritis, ANCA vasculitis, and systemic sclerosis, to assessing the efficacy of guselkumab, deucravacitinib, secukinumab, bimekizumab, and sonelokimab in psoriatic arthritis, to assessing the efficacy of upadacitinib in Spondyloarthritis and PsA. He is also the PI on the SAGE-PsA Study looking at sex and gender based analysis of the effectiveness of advanced therapies in PsA. Fellows will have opportunity to participate in small ‘compact’ clinical projects in the field of psoriatic arthritis and spondyloarthritis, and writing case reports, case series, and review articles.

Selected Publications:

1. Deodhar A, Navarro-Compán V, Poddubnyy D, Gensler LS, Ramiro S, Tomita T, Marzo-Ortega H, Fleurinck C, Vaux T, Massow U, de Peyrecave N, van der Heijde D, Baraliakos X. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025 Jan 31;11(1):e005081.
2. Deodhar A, Akar S, Curtis JR, El-Zorkany B, Magrey M, Wang C, Wu J, Makgoeng SB, Vranic I, Menon S, Fleishaker DL, Diehl AM, Fallon L, Yndestad A, Landewé RBM. Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. Adv Rheumatol. 2024 Dec 18;64(1):87.
3. Deodhar A, Supronik J, Kivitz A, Valenzuela G, Kapur K, Rohrer S, Dokoupilová E, Richards HB, Pavelka K. Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study. Arthritis Rheumatol. 2024 Sep 19. doi: 10.1002/art.42993. Online ahead of print.
4. Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, Kianifard F, Elam C, Bommidi GM, Winseck A, Gensler LS. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford). 2024 Aug 12:keae432. doi: 10.1093/rheumatology /keae432. Online ahead of print.
5. Deodhar A, Raychaudhuri SP, Boehncke WH, de Vlam K, Chandran V, Liao W. Advances in Psoriatic Disease Research: Insights From GRAPPA Pilot Research Awardees. J Rheumatol. 2024 Jul 15:jrheum.2024-0292.

Julianna Desmarais, MD

Dr. Desmarais is an academic rheumatologist and educator. She is co-director of the Interstitial Lung Disease (ILD) Clinic at OHSU, a combined rheumatology-pulmonology collaboration to care for multisystem diseases. Current projects in education include authoring several Rheum2Learn 2.0 interactive cases for the American College of Rheumatology website, participating in the resident comparison and feedback about Rheum2Learn 2.0 versus the original Rheum2Learn cases to evaluate the impact of the interactive modules, and creating MSK Bingo and an Escape-Rheum as part of a gamification project for rheumatology fellows’ learning.  Projects in ILD include characterizing the OHSU cohort of patients with Sarcoidosis with ILD and extra-pulmonary manifestations, participation in the Scleroderma ILD CONQUEST trial which is a global, perpetual, platform clinical trial developed by the Scleroderma Research Foundation (SRF) in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. Her goal is for the OHSU ILD Clinic to participate in future RA-ILD treatment trials. Fellows and residents are welcome to help with the sarcoidosis registry and may contribute ideas to projects relating to making rheumatology education fun and accessible.

Selected Publications:

1. Rosenbaum JT, Fett N, Ghetie D, Desmarais J. Is Collaborative Care Better Care? Arthritis Care Res (Hoboken). 2025 Mar;77(3):297-299. doi: 10.1002/acr.25434. Epub 2024 Oct 15. PMID: 39295234.
2. Su J, Desmarais J, Chu CQ, Zhu J. Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2024 May;38(2):101945. doi: 10.1016/j.berh.2024.101945. Epub 2024 Apr 15. PMID:38627168
3. Anderson E, Beier S, Desmarais J. Certolizumab pegol in the treatment of axial spondyloarthritis. Immunotherapy. 2024 Mar 26. doi: 10.2217/imt-2023-0225. Epub ahead of print. PMID: 38530074.
4. Desmarais J, Rosenbaum JT, Costenbader KH, Ginzler EM, Fett N, Goodman S, O'Dell J, Pineau CA, Schmajuk G, Werth VP, Link MS, Kovacs R. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021 Dec;73(12):2151-2160. doi: 10.1002/art.41934. Epub 2021 Oct 26. PMID: 34697918.
5. Friedman MA, Le B, Stevens J, Desmarais J, Seifer D, Ogle K, Choi D, Harrington CA, Jackson P, Rosenbaum JT. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung. 2021 Apr;199(2):147-153. doi: 10.1007/s00408-021-00436-8. Epub 2021 Apr 7. PMID: 33825964

Whitney Elg-Salsman, DO, MCR

Dr. Elg-Salsman’s academic and clinical interests include immune-related adverse effects (irAEs) of immunotherapy, Systemic Lupus Erythematosus, Systemic Sclerosis and Interstitial Lung Disease. She is the director of the OHSU SLE/Scleroderma Clinic and established and heads the OHSU irAE Clinic dedicated to the diagnosis and management of the musculoskeletal side effects that can occur with ICI therapy. Dr. Elg-Salsman completed a Masters in Clinical Research at the Medical University of South Carolina where she focused her research on studying rheumatic irAEs and identifying biomarkers that would serve as predictors of irAE risk.  Dr. Elg-Salsman’s current research project, “Unbiased discovery and validation of serum auto-antibodies and validation of serum auto-antibodies in pts with rheumatic irAEs due to ICI”, is a multi-center project that hopes to answer this important question. Fellows may be involved in retrospective chart reviews and data collection that would help address these important questions regarding risk factors but also optimal treatment algorithms for rheumatic irAEs. 
Publications:
Elg-Salsman et al. A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience. Abstract 1809, ACR Scientific Meeting, Podium Presentation, 2019. 

Gina Ferrero, MD

Dr. Gina Ferrero is a rheumatologist and clinician-educator at Oregon Health & Science University with a focus on improving access to rheumatologic care for rural and underserved populations. She leads Oregon’s first Musculoskeletal and Rheumatology Project ECHO®—a virtual, case-based learning platform designed to build clinical capacity among rural providers through specialist-led didactics and interactive case discussions. The inaugural 12-week series had strong engagement, with 81% of enrolled providers attending at least one session and an average of 9 sessions attended per participant. Post-session surveys showed high satisfaction (average ratings of 4.6 to 4.9 on a 5-point scale), and retrospective pre/post surveys demonstrated significant gains in provider confidence, particularly in initiating treatment for conditions like giant cell arteritis. Supported by the Oregon ECHO Network and anticipated external grants, this project is the first to evaluate the impact of rheumatology ECHO on referral quality and provider behavior, using a novel selection model. A trainee may contribute by supporting evaluation efforts, assisting with data analysis, and participating in scholarly dissemination.

Kamini Kuchinad, MD, MPH

Dr. Kuchinad is an early career physician in rheumatology at the Portland VA. During medical school, she completed her Masters in Public Health with a focus in biostatistics and epidemiology at the Johns Hopkins University School of Medicine. She completed her clinical and research (T32) fellowships at the Johns Hopkins University School of Medicine Division of Rheumatology. During this time, her research focused on identifying drivers of health inequity among individuals with systemic sclerosis and improving the way we communicate with individuals with complex rheumatic disease. Her current research interests involve improving the quality of care for individuals with complex rheumatic disease, with a specific interest in cultivating  communication and trust in the clinician-patient relationship. Residents and fellows interested in exploring clinical rheumatology or health services research are welcome to join her research team.

Selected Publications

1. Adler BL, Kuchinad K, Jeong SJ, Stiles LE, Shah AA, Chung T, McMahan ZH. Colour changes in the feet: a sign of autonomic symptoms in systemic sclerosis. Rheumatology (Oxford). 2025 May 1;64(5):3080-3084. doi:      10.1093/rheumatology/keae516. PMID: 39302703; PMCID: PMC12048065.
2. Kuchinad KE, Kim JS, Woods A, Leatherman G, Gutierrez-Alamillo L, Mayes MD, Domsic R, Ramos PS, Silver RM, Varga J, Saketkoo LA, Kafaja S, Shanmugan VK, Gordon J, Chung L, Bernstein EJ, Gourh P, Boin F, Kastner DL, Zeger SL, Casciola-Rosen L, Wigley FM, Shah AA. Racial variability in immune responses only partially explains differential systemic sclerosis disease severity. Ann Rheum Dis. 2024 Oct 21;83(11):1513-1521. doi: 10.1136/ard-2023-225458. PMID:39019570; PMCID: PMC11875133.
3. Kuchinad K, Park JR, Han D, Saha S, Moore R, Beach MC. Which clinician responses to emotion are associated with more positive patient experiences of communication? Patient Educ Couns. 2024 Jul;124:108241. doi:10.1016/j.pec.2024.108241. Epub 2024 Mar 8. PMID: 38537316.
4. Kuchinad K, Nadeem M, Mehta AK, Wu DS, Harris CM, Albayda J. Palliative Care Utilization for Hospitalized Patients With Inclusion Body Myositis: A Nationwide Study. J Clin Rheumatol. 2023 Sep 1;29(6):e130-e133. doi:10.1097/RHU.0000000000001997. Epub 2023 Jun 28. PMID: 37370210.
5. Kuchinad K, Sharma R, Isenberg SR, Hamayel NAA, Weaver SJ, Zhu J, Hannum SM, Kamal AH, Walling AM, Lorenz KA, Ailon J, Dy SM. Perceptions of Facilitators and Barriers to Measuring and Improving Quality in Palliative Care Programs. Am J Hosp Palliat Care. 2020 Dec;37(12):1022-1028. Epub 2020 Apr 27. PMID: 32336104.

Ingrid Lindquist, MD

Dr. Lindquist is an early career physician scientist in rheumatology and is growing a highly collaborative research program at the VA. She completed both clinical and research (T32) fellowships at OHSU. Prior to medicine, she worked in genomics at the National Center for Genome Resources. She is now focused on distilling rheumatology's large transcriptomic datasets to their biologic and clinical relevance. Her primary focus is currently on sarcoidosis and giant cell arteritis, however sees the structure of her research applicable to many complex rheumatic diseases. Residents and fellows are welcome to join her in research and expand their skill sets in rheumatology and genomics including pathway analysis and drug-repurposing.

Recent Selected Publications:

1. Kiana Vakil-Gilani, Ingrid Lindquist, Marcia Friedman and Kevin L. Winthrop. Chapter 120. Vaccination in Rheumatic Disease, Firestein & Kelley’s Textbook of Rheumatology, 120, 2095-2104.e4
2. Lindquist, Choi, Fei, Vakil-Gilani, Ghetie, Wilson, Salomao, Stiefel, Albert, Rosenbaum, Friedman. Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls. Arthritis Rheumatol. 2024; 76 (suppl 9).
3. Gill T, Stauffer P, Asquith M, Laderas T, Martin TM, Davin S, Schleisman M, Ramirez C, Ogle K, Lindquist I, et al. Axial spondyloarthritis patients have altered mucosal IgA response to oral and fecal microbiota. Front Immunol. 2022.
4. Lindquist, Rosenbaum, Friedman (2022). Podium presentation at ACR. Solving Sarcoidosis: A transcriptome-based metaanalysis of clinical sarcoidosis studies illustrates shared pathophysiology, identifies candidate biomarkers and suggests a therapeutic mechanism of JAK inhibition. Arthritis & Rheumatology 74, 2205-2206.
5. Lindquist, Olson, Li, Jou, Al-Samkari, McCarty, Shatzel. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2021

Pascale Schwab, MD

Dr. Schwab’s primary focus is patient care and the education of the rheumatology fellows. Her academic interests include rheumatoid arthritis, crystalline arthritis, and osteoporosis. She is the site PI for the Veterans Affairs Rheumatoid Arthritis (VARA) Registry, a multicenter longitudinal patient registry of US Veterans with rheumatoid arthritis and was on the literature review task force effort behind the 2021 ACR Rheumatoid Arthritis Treatment Guidelines. As the Portland site investigator, she participated in the STOP-GOUT trial, a multicenter non-inferiority randomized controlled VA Cooperative Study that compared allopurinol to febuxostat in gout patients. She welcomes fellows interested in asking research questions that can be answered utilizing the VARA database as well as fellows looking to collaborate on a range of VA-based QI projects.

Selected Publications:

1. McGoldrick J, Molina-Ochoa D, Schwab P, Edwards ST, Barton JL. An Evaluation of Burnout Among US Rheumatology Fellows: A National Survey. J Rheumatol. 2023 Sep;50(9):1185-1190.
2. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-1123.
3. Ebel AV, Lutt G, Poole JA, Thiele GM, Baker JF, Cannon GW, Gaffo A, Kerr GS, Reimold A, Schwab P, Singh N, Richards JS, Ascherman DP, Mikuls TR, England BR. Association of Agricultural, Occupational, and Military Inhalants With Autoantibodies and Disease Features in US Veterans With Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Mar;73(3):392-400.
4. Schwab P, Sayles H, Bergman D, Cannon GW, Michaud K, Mikuls TR, Barton J. Utilization of Care Outside the Veterans Affairs Health Care System by US Veterans With Rheumatoid Arthritis. Arthritis Care Res Hoboken). 2017 Jun;69(6):776-782.
5. England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, Sauer BC, Solow EB, Reimold AM, Kerr GS, Schwab P, Baker JF, Mikuls TR. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):36-45.

OHSU Rheumatology Fellows’ Publications (2018-current)

Book Chapters & Articles

Cubberley C, Maharaj A. Global RA treatment recommendations: An update from the various international societies. Best Pract Res Clin Rheumatol. 2025 Mar;39(1):102019. doi: 10.1016/j.berh.2024.102019. Epub 2024 Nov 3. PMID: 39496528.

Anderson E, Beier S, Desmarais J. Certolizumab pegol in the treatment of axial spondyloarthritis. Immunotherapy. 2024 Mar 26. doi: 10.2217/imt-2023-0225. Epub ahead of print. PMID: 38530074

Gandiga PC, Ghetie D, Anderson E, Aggrawal R. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use. Curr Rheumatol Rep. 2023 Aug;25(8):152-168. doi: 10.1007/s11926-023-01105-w. Epub 2023 Jun 1. PMID: 37261663.

Vakil-Gilani K, Cordova T, Seifer D, Deodhar A. Book Chapter: “Pulmonary manifestations of axial spondyloarthritis”. Interdisciplinary Rheumatology: Rheumatology & Pulmonary, 2023.

Vakil-Gilani K, Lindquist I, Friedman M, Winthrop K. Book Chapter: “Vaccine recommendations in rheumatic patients on immunosuppressive therapy”. Firestein & Kelley’s Textbook of Rheumatology, 2023.

Vakil-Gilani K, Deodhar A. Book Chapter: “Spondyloarthritis treatments”. Straight Talk on Spondylitis. 2022.

McGoldrick J, Molina-Ochoa D, Schwab P, Edwards ST, Barton JL. An Evaluation of Burnout Among US Rheumatology Fellows: A National Survey. J Rheumatol. 2023 Sep;50(9):1185-1190. PMID: 36921966

Lindquist I, Deodhar A. Expert commentary on “Recapture and retreatment rates with ixekizumab after withdrawal of therapy of therapy in axial SpA. www.practiceupdate.com. 2022.

Gill T, Stauffer P, Asquith M, Laderas T, Martin TM, Davin S, Schleisman M, Ramirez C, Ogle K, Lindquist I, Nguyen J, Planck SR, Shaut C, Diamond S, Rosenbaum JT, Karstens L. Axial spondyloarthritis patients have altered mucosal IgA response to oral and fecal microbiota. Front Immunol. 2022 Sep 28;13:965634. PMID: 36248884

Mathapathi S, Chu CQ. Contribution of Impaired DNASE1L3 Activity to Anti-DNA Autoantibody Production in Systemic Lupus Erythematosus. Rheumatol Immunol Res. 2022 Apr 20;3(1):17-22. PMID: 36467024

Wei M, Chu CQ. Prediction of treatment response: Personalized medicine in the management of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022 Mar;36(1):101741. PMID: 35063347

Stienstra N, Horton J, Lane M, Kumthekar A, Sathe N, Sunny C, Yadav V, Deodhar A. Demyelinating Disease After Exposure to Tumor Necrosis Factor α Inhibitors: A Case Series in a Tertiary Care Center. J Clin Rheumatol. 2022 Mar 1;28(2):e638-e641. PMID: 34538848

Stienstra N, Barton JL. Book Chapter: “Seeking New Voices and Perspectives for Healthcare in America: Recognizing and Overcoming Barriers of Language” 2021.

Ringsted S, Friedman M. A rheumatologic approach to granulomatous mastitis: A case series and review of the literature. Int J Rheum Dis. 2021 Apr;24(4):526-532. PMID: 33523600 

Lewis JS, Sharma A, Horton JB, Deodhar A, Modiano N. Lupus-associated protein losing enteropathy (LUPLE) complicated by a hypercoagulable state and successfully treated with belimumab. Clin J Gastroenterol. 2020 Oct;13(5):771-774. PMID: 32734316

Rice J, Woltjer R, Stienstra N, Sun E, Yadav V. Pearls & Oy-sters: Primary angiitis of the CNS presenting with recurrent intracranial hemorrhage. Neurology. 2020 Mar 3;94(9):e992-e995. PMID: 32041724

Kiwalkar S, Beier S, Deodhar A. Ixekizumab for treating ankylosing spondylitis. Immunotherapy. 2019 Oct;11(15):1273-1282. PMID: 31530049

Kumthekar A, Raess PW, Ghetie D. A Missing Link: Sarcoid-Lymphoma Syndrome. Am J Med. 2019 Jan;132(1):48-51. PMID: 30102910

McCulley CB, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2019 May-Jun;37(3):422-428. PMID: 30418120

McCulley C, Katz P, Trupin L, Yelin EH, Barton JL. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis. J Rheumatol. 2018 Dec;45(12):1636-1642. PMID: 30219761

Kumthekar A, Woltjer R, Schwab P. More than meets the eye: A case of HCV-induced PAN. Modern Rheum. 2018; 2(2):199-203.

Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018 Jan;101:78-88 . PMID: 27688201

Abstracts

Vakil-Gilani K, Cordova T, Seifer D, Deodhar A. Pulmonary manifestations of axial spondylarthritis. EULAR 2023.

Lindquist I, Rosenbaum J, Friedman M. Solving sarcoidosis: A transcriptome-based meta-analysis of clinical sarcoidosis studies illustrates shared pathophysiology, examines mediators of fibrosis biomarkers and suggests a therapeutic mechanism of JAK inhibition. EULAR 2023.

Lindquist I, Rosenbaum J, Friedman M. Solving sarcoidosis: A transcriptome based meta-analysis of clinical sarcoidosis studies illustrates shared pathophysiology, examines mediators of fibrosis biomarkers and suggests a therapeutic mechanism of JAK inhibition. ACR Convergence 2022.

Ringsted S, Sathe N, Deodhar A, Choi D. An artificial intelligence assistant identifying spinal diffuse idiopathic hyperostosis on plain x-rays: A pilot deep learning study. ACR Convergence 2020.

Stienstra N, Lane M, Horton J, Kumtehkar A, Sathe N, Deodhar A. Tumor necrosis factor alpha and demyelinating disease: Long-term outcomes from a single center. EULAR 2020.

Elg-Salsman W, Zhou , Friedman M, Kiwalkar S. A quarter of patients treated with checkpoint inhibitors develop immune related adverse events: A university experience. ACR Meeting 2019

Ringsted S, Friedman M. Idiopathic granulomatous mastitis: The role of rheumatologists in treating this rare cause of breast pain. ACR meeting 2019. McGoldrick J, Molina D, Edwards S, Schwab P, Barton J. An evaluation of burnout among US rheumatology fellows: a national survey. ACR meeting 2019.

Kiwalkar S, Deodhar A. Oregon Chiropractic practices and prevalence of AxSpA. SPARTAN 2019.

Kiwalkar S, Hay J, Howard R, Deodhar A, Rosenbaum J. Assessing burden in patients with psoriatic SpA and axial SpA. GRAPPA 2018.

McCulley C, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. ACR Meeting 2018.

McCulley C, Keller J, Wanchu A. Not all vegetables are good for you: A case of vegetative lesions to stump the team. ACR Meeting 2018.

The Oregon Clinical & Translational Research Institute provides a coordinated infrastructure of core research tools to serve clinical research investigators and research staff.